61 completed, 21 unknown, 8 terminated, 5 recruiting. 26 Phase 3, 26 Phase 4, 18 Phase 1, 18 Phase 2, 11 Not applicable.
Follow candesartan: new trials by email Literature Review of candesartan trials Research Report on candesartan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy Spironolactone (drug), Candesartan 8mg, Hydrochlorothiazide (HCTZ) 25 milligrams. - Hypertension | Phase 4 | Not yet recruiting | Ottawa Hospital Research Institute | 30 | 2027-01-01 | 2026-10-14 |
| Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM) Galcanezumab, Erenumab 70 mg, Eptinezumab - Migraine Associated Vertigo, Tinnitus | Phase 4 | Not yet recruiting | Stanford University | 120 | 2026-07-01 | 2026-06-17 |
| Improved Treatment and Monitoring of Alzheimer's Disease Semaglutide (Rybelsus®) combined with other interventions, Placebo, Semaglutide (Rybelsus®) - Alzheimer Disease (AD) | Phase 2 | Not yet recruiting | Rune Skovgaard Rasmussen | 180 | 2026-01-01 | 2025-08-22 |
| To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe - Hypertension, Primary Hypercholesterolaemia | Phase 3 | Enrolling by invitation | Hyundai Pharm | 125 | 2025-04-22 | 2025-05-22 |
| Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial) Candesartan - Cardiomyopathy, Dilated | Phase 3 | Recruiting | Cristina Avendaño Solá | 320 | 2022-06-02 | 2024-11-07 |
| Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension SPC1001 High, SPC1001 Mid1, SPC1001 Mid2 - Hypertension, Essential Hypertension | Phase 2 | Completed | Shin Poong Pharmaceutical Co. Ltd. | 253 | 2022-03-25 | 2024-01-19 |
| Post-traumatic Headache Multidisciplinary Study Candesartan - Post-Traumatic Headache, Post-Concussion Syndrome | Completed | Danish Headache Center | 58 | 2021-09-01 | 2025-01-29 | |
| Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography Continue ACEI or ARBs ( Enalapril , Ramipril , Valsartan , Candesartan, Losartan ), Hold ACEI or ARBs - Contrast-induced Nephropathy, Chronic Kidney Diseases | Not applicable | Unknown | An-Najah National University | 600 | 2021-06-01 | 2023-06-06 |
| Candesartan for Migraine Prevention: Candesartan Oral Tablet 8 mg, Candesartan Oral Tablet 16 mg, Placebo oral tablet - Migraine | Phase 2 | Completed | St. Olavs Hospital | 450 | 2021-04-09 | 2025-08-13 |
| Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty sacubitril/valsartan, Angiotensin II Receptor Blockers - Heart Failure, Systolic, Frailty | Unknown | Brigham and Women's Hospital | 40000 | 2021-01-14 | 2021-02-15 | |
| Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Losartan, Valsartan, Azilsartan - Covid19, SARS-CoV Infection | Phase 3 | Terminated | University of British Columbia | 341 | 2020-10-09 | 2023-02-16 |
| Candesartan as an Adjunctive Treatment for Bipolar Depression Candesartan, Placebo - Bipolar Disorder Depression | Early Phase 1 | Withdrawn | The University of Texas Health Science Center, Houston | 2020-10-01 | 2022-04-27 | |
| Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Angiotensin Receptor Blockers, Placebo - Coronavirus Disease 2019, COVID-19 | Phase 4 | Completed | The George Institute | 787 | 2020-06-19 | 2022-03-17 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care - COVID-19 | Phase 2 / Phase 3 | Unknown | Medical University of Vienna | 500 | 2020-04-16 | 2021-03-02 |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| CandeSpartan Study. Candesartan Spanish Response-prediction and Tolerability Study Candesartan - Migraine, Head Pain | Completed | Hospital Clínico Universitario de Valladolid | 85 | 2020-01-02 | 2022-12-19 | |
| Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension QUARTET LDQT, Candesartan - Hypertension | Phase 2 | Completed | Washington University School of Medicine | 62 | 2019-08-30 | 2025-01-03 |
| Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer Candesartan - Cardiotoxicity, Breast Cancer | Not applicable | Unknown | Samsung Medical Center | 136 | 2019-07-19 | 2020-06-12 |
| Candesartan in Peripheral Neuropathy Candesartan, Usual care - Peripheral Neuropathy | Phase 2 | Terminated | University Hospital, Limoges | 9 | 2019-05-01 | 2021-11-15 |
Showing 20 of 105. Sign in to see all of them.
Hypertension (40) · Heart Failure (8) · Essential Hypertension (7) · Cardiovascular Diseases (6) · COVID-19 (5) · Diabetes Mellitus, Type 2 (5) · Obesity (5) · Insulin Resistance (4) · Renal Insufficiency, Chronic (4) · Cognitive Dysfunction (3) · Diabetes Mellitus (3) · Diabetes Mellitus, Type 1 (3) · Migraine Disorders (3) · Obesity, Abdominal (3) · Alzheimer Disease (2)
AstraZeneca (9) · Chong Kun Dang Pharmaceutical (8) · Mayo Clinic (3) · Takeda (3) · Alvogen Korea (2) · Bayer (2) · Baylor College of Medicine (2) · EMS (2) · Emory University (2) · Medical University of Vienna (2) · Norwegian University of Science and Technology (2) · Saitama Medical University (2) · Technische Universität Dresden (2) · Third Military Medical University (2) · Vanderbilt University (2)
United States (19) · South Korea (13) · Germany (8) · Denmark (5) · France (5) · Japan (5) · Norway (5) · Spain (5) · Sweden (5) · United Kingdom (5) · Canada (4) · Italy (4) · Austria (3) · Australia (2) · China (2)
Jang Hee Hong (3) · Ihab Hajjar, MD (2) · Kyun-Seop Bae, Professor (2) · Wilhelm Kirch, MD (2) · Abeer El-Motwally, Msc (1) · Adam P Bress, PharmD, MS (1) · Anders F Edebo, MD PhD (1) · Arnljot Tveit, MD (1) · Bernd Jilma, MD (1) · Birger Thorsteinsson, Prof DMSc MD (1) · Bjorn Eriksson, MD (1)
PMID 19196892, PMID 25326006, PMID 29431256, PMID 37366061, PMID 19451554, PMID 21225239, PMID 21309844, PMID 34473343, PMID 38682786, PMID 16959033, PMID 17113170, PMID 17922981, PMID 18270751, PMID 18372389, PMID 18539917, PMID 18653268, PMID 18823656, PMID 18823658, PMID 19074594, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 21353251, PMID 21366473, PMID 21602709, PMID 21663644, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22093207, PMID 22179956, PMID 22374637, PMID 22412114, PMID 22413836, PMID 22432114, PMID 22440088, PMID 22450889, PMID 22515638, PMID 22525206, PMID 22549281, PMID 22619083, PMID 22646230, PMID 22723577
2005 (1), 2008 (1), 2015 (1), 2019 (1), 2023 (1), K23AG030057 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1), P01HL069999 (1), P50DA018197 (1)